Trillium Therapeutics Inc.
TRIL.TO
Toronto Stock Exchange23.33
CAD
- -
- -
Trillium Therapeutics Inc.
TRIL.TO
(Toronto Stock Exchange)
Recent
price
23.33
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Trillium Therapeutics Inc. Trillium Therapeutics Inc. is a clinical-stage immuno-oncology company focused on developing innovative therapies that target immune-regulatory pathways exploited by cancer cells to evade the host immune system; its lead product candidates include TTI-622, a SIRPα-IgG4 Fc fusion protein designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47 "don't eat me" signal in advanced relapsed or refractory lymphoma and multiple myeloma (Phase 1a/1b trials, NCT03530683), and TTI-621, a SIRPα-IgG1 Fc fusion protein generating antibody-dependent cellular cytotoxicity alongside CD47 blockade for hematologic malignancies, solid tumors, and mycosis fungoides (Phase 1 trials); the company also advances preclinical programs in oncology. Founded in 2003 and headquartered in Cambridge, Ontario, Canada, Trillium operates primarily in North America with a focus on hematological malignancies and solid tumors, serving patients through clinical research in the biotechnology sector. In November 2021, Pfizer Inc. completed its acquisition of Trillium for approximately $2.26 billion, integrating its CD47-targeting portfolio into Pfizer's oncology research and development efforts to accelerate advancement across multiple indications.